[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 55 of about 55
1. Jayachandran G, Ueda K, Wang B, Roth JA, Ji L: NPRL2 sensitizes human non-small cell lung cancer (NSCLC) cells to cisplatin treatment by regulating key components in the DNA repair pathway. PLoS One; 2010 Aug 05;5(8):e11994
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] NPRL2 sensitizes human non-small cell lung cancer (NSCLC) cells to cisplatin treatment by regulating key components in the DNA repair pathway.
  • NPRL2, one of the tumor suppressor genes residing in a 120-kb homozygous deletion region of human chromosome band 3p21.3, has a high degree of amino acid sequence homology with the nitrogen permease regulator 2 (NPR2) yeast gene, and mutations of NPRL2 in yeast cells are associated with resistance to cisplatin-mediated cell killing.
  • Previously, we showed that restoration of NPRL2 in NPRL2-negative and cisplatin-resistant cells resensitize lung cancer cells to cisplatin treatment in vitro and in vivo.
  • In this study, we show that sensitization of non-small cell lung cancer (NSCLC) cells to cisplatin by NPRL2 is accomplished through the regulation of key components in the DNA-damage checkpoint pathway.
  • Moreover, this combination treatment results in higher Chk1 and Chk2 kinase activity than does treatment with cisplatin alone and can activate Chk2 in pleural metastases tumor xenograft in mice.
  • Activated Chk1 and Chk2 increase the expression of cell cycle checkpoint proteins, including Cdc25A and Cdc25C, leading to higher levels of G2/M arrest in tumor cells treated with NPRL2 and cisplatin than in tumor cells treated with cisplatin only.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2000 Mar 31;275(13):9390-5 [10734083.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9682-90 [17018626.001]
  • [Cites] Science. 2000 May 26;288(5470):1425-9 [10827953.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10389-94 [10973490.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6116-33 [11085536.001]
  • [Cites] Nature. 2000 Nov 23;408(6811):433-9 [11100718.001]
  • [Cites] Mol Pharmacol. 2001 Apr;59(4):657-63 [11259608.001]
  • [Cites] Nature. 2001 Apr 12;410(6830):842-7 [11298456.001]
  • [Cites] Mol Cell Biol. 2001 Jul;21(13):4129-39 [11390642.001]
  • [Cites] Genes Dev. 2001 Jul 15;15(14):1833-44 [11459832.001]
  • [Cites] J Biol Chem. 2001 Nov 9;276(45):42462-7 [11571274.001]
  • [Cites] Curr Opin Cell Biol. 2001 Dec;13(6):738-47 [11698191.001]
  • [Cites] Cell Death Differ. 2002 Jan;9(1):27-39 [11803372.001]
  • [Cites] Genes Dev. 2002 Mar 1;16(5):571-82 [11877377.001]
  • [Cites] Nat Genet. 2002 Mar;30(3):290-4 [11850621.001]
  • [Cites] J Biol Chem. 2002 May 3;277(18):16102-15 [11821419.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2715-20 [11980673.001]
  • [Cites] Science. 2002 May 3;296(5569):922-7 [11934988.001]
  • [Cites] Mol Cell Biol. 2002 Jun;22(12):4419-32 [12024051.001]
  • [Cites] J Biol Chem. 2002 May 31;277(22):19389-95 [11901158.001]
  • [Cites] J Biol Chem. 2002 Aug 16;277(33):29803-9 [12065594.001]
  • [Cites] Science. 2002 Aug 23;297(5585):1352-4 [12193789.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2963-9 [12231542.001]
  • [Cites] Oncogene. 2002 Oct 7;21(45):6915-35 [12362274.001]
  • [Cites] EMBO J. 2002 Nov 1;21(21):5911-20 [12411508.001]
  • [Cites] Nat Cell Biol. 2002 Dec;4(12):993-7 [12447390.001]
  • [Cites] Nature. 2003 Feb 27;421(6926):961-6 [12607005.001]
  • [Cites] Genes Dev. 2003 Mar 1;17(5):615-28 [12629044.001]
  • [Cites] J Biol Chem. 2003 Apr 25;278(17):14806-11 [12588868.001]
  • [Cites] Nat Cell Biol. 2003 Jul;5(7):675-9 [12792649.001]
  • [Cites] EMBO Rep. 2003 Jul;4(7):671-7 [12835754.001]
  • [Cites] Mol Pharmacol. 2003 Aug;64(2):259-68 [12869630.001]
  • [Cites] Cell. 2003 Aug 8;114(3):371-83 [12914701.001]
  • [Cites] Curr Opin Genet Dev. 2004 Feb;14(1):11-6 [15108799.001]
  • [Cites] J Natl Cancer Inst. 1990 May 2;82(9):749-55 [1691303.001]
  • [Cites] Cancer Cells. 1990 Aug-Sep;2(8-9):275-80 [2223389.001]
  • [Cites] Biochem Pharmacol. 1990 Nov 15;40(10):2353-62 [2244936.001]
  • [Cites] Cancer Res. 1994 Mar 15;54(6):1596-603 [8137265.001]
  • [Cites] Science. 1997 Sep 5;277(5331):1497-501 [9278511.001]
  • [Cites] Science. 1997 Sep 5;277(5331):1501-5 [9278512.001]
  • [Cites] Cancer Res. 1997 Oct 15;57(20):4488-92 [9377558.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7514-9 [9636181.001]
  • [Cites] Science. 1998 Dec 4;282(5395):1893-7 [9836640.001]
  • [Cites] Cancer Treat Rev. 1998 Oct;24(5):331-44 [9861196.001]
  • [Cites] Eur J Cancer. 1998 Sep;34(10):1535-42 [9893624.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3745-50 [10097108.001]
  • [Cites] Cancer Res. 1999 Jul 15;59(14):3333-9 [10416589.001]
  • [Cites] Oncogene. 1999 Jul 15;18(28):4047-54 [10435585.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1949-60 [10766185.001]
  • (PMID = 20700484.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-16672; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50CA70907; United States / NCI NIH HHS / CA / R01 CA116322; United States / NCI NIH HHS / CA / R01CA116322; United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / U01CA10535201
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / H2AFX protein, human; 0 / Histones; 0 / NBN protein, human; 0 / NPRL2 protein, human; 0 / Nuclear Proteins; 0 / Tumor Suppressor Proteins; EC 2.7.- / Protein Kinases; EC 2.7.1.11 / Checkpoint Kinase 2; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Atm protein, mouse; EC 2.7.11.1 / CHEK2 protein, human; EC 2.7.11.1 / Checkpoint kinase 1; EC 2.7.11.1 / Chek2 protein, mouse; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 3.4.22.- / Caspases; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2916838
  •  go-up   go-down


2. Giordano S, Pampinella D, Alù M, Agostara B, Romano A: [EBV reactivation in a patient undergoing chemotherapy for invasive thymoma]. Infez Med; 2007 Sep;15(3):195-8
MedlinePlus Health Information. consumer health - Thymus Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Riattivazione di EBV in un paziente sottoposto a chemioterapia per metastasi da timoma misto invasivo.
  • In October 2006, a 53-year-old man with pulmonary and pleural metastases owing to an invasive thymoma, was started on chemotherapy with cisplatin, adriamycin and cyclophosphamide.
  • [MeSH-minor] Humans. Male. Middle Aged. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17940405.001).
  • [ISSN] 1124-9390
  • [Journal-full-title] Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive
  • [ISO-abbreviation] Infez Med
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


3. An Z, Dobra K, Lock JG, Strömblad S, Hjerpe A, Zhang H: Kindlin-2 is expressed in malignant mesothelioma and is required for tumor cell adhesion and migration. Int J Cancer; 2010 Nov 1;127(9):1999-2008
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kindlin-2 is expressed in malignant mesothelioma and is required for tumor cell adhesion and migration.
  • Focal adhesion proteins control cytoskeleton dynamics and promote cancer cell growth, survival, migration and metastasis.
  • Little is known, however, about expression of Kindlin-2 in association with human cancer.
  • We now reveal high Kindlin-2 expression in malignant mesothelioma (MM) cell lines using an affinity-purified anti-Kindlin-2 antibody.
  • In addition, Kindlin-2 expression correlates to cell proliferation, suggesting a role for Kindlin-2 in tumor growth.
  • Besides the high expression of Kindlin-2 in pleural MMs, pleural metastases of lung adenocarcinoma also express large amounts of Kindlin-2, but not Kindlin-1.
  • Overall, our study suggests that heightened expression of Kindlin-2 might contribute to tumor progression in MM.
  • [MeSH-major] Lung Neoplasms / metabolism. Membrane Proteins / metabolism. Mesothelioma / metabolism. Neoplasm Proteins / metabolism. Pleural Neoplasms / metabolism
  • [MeSH-minor] Cell Adhesion. Cell Line, Tumor. Cell Movement. Cell Proliferation. Disease Progression. Humans. Neoplasm Invasiveness. Neoplasm Metastasis. Protein-Serine-Threonine Kinases / metabolism

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20127858.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FERMT1 protein, human; 0 / MIG2B protein, human; 0 / Membrane Proteins; 0 / Neoplasm Proteins; EC 2.7.1.- / integrin-linked kinase; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


Advertisement
4. Jones GE, Strauss DC, Forshaw MJ, Deere H, Mahedeva U, Mason RC: Breast cancer metastasis to the stomach may mimic primary gastric cancer: report of two cases and review of literature. World J Surg Oncol; 2007;5:75
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer metastasis to the stomach may mimic primary gastric cancer: report of two cases and review of literature.
  • BACKGROUND: The stomach is an infrequent site of breast cancer metastasis.
  • It may prove very difficult to distinguish a breast cancer metastasis to the stomach from a primary gastric cancer on the basis of clinical, endoscopic, radiological and histopathological features.
  • It is important to make this distinction as the basis of treatment for breast cancer metastasis to the stomach is usually with systemic therapies rather than surgery.
  • CASE PRESENTATIONS: The first patient, a 51 year old woman, developed an apparently localised signet-ring gastric adenocarcinoma 3 years after treatment for lobular breast cancer with no clinical evidence of recurrence.
  • Immunohistochemistry for Gross Cystic Disease Fluid Protein was positive, suggesting metastatic breast cancer.
  • The second patient, a 61 year old woman, developed a proximal gastric signet-ring adenocarcinoma 14 years after initial treatment for breast cancer which had subsequently recurred with bony and pleural metastases.
  • In this case, initial gastric biopsies were positive for both oestrogen and progesterone receptors; subsequent investigations revealed widespread metastases and surgery was avoided.
  • CONCLUSION: In patients with a history of breast cancer, a high index of suspicion for potential breast cancer metastasis to the stomach should be maintained when new gastrointestinal symptoms develop or an apparent primary gastric cancer is diagnosed.
  • Complete histopathological and immunohistochemical analysis of the gastric biopsies and comparison with the original breast cancer pathology is important.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Lobular / diagnosis. Carcinoma, Lobular / secondary. Stomach Neoplasms / diagnosis. Stomach Neoplasms / secondary
  • [MeSH-minor] Carcinoma, Signet Ring Cell / diagnosis. Diagnosis, Differential. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endoscopy. 2004 Jun;36(6):543-50 [15202052.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Sep;31(3):701-13 [12481726.001]
  • [Cites] Am J Dig Dis. 1972 Oct;17(10):881-6 [5073677.001]
  • [Cites] J Biol Chem. 1973 Aug 25;248(16):5736-41 [4723913.001]
  • [Cites] Am J Dig Dis. 1975 Oct;20(10):903-13 [1190198.001]
  • [Cites] Ann Surg. 1977 Mar;185(3):279-85 [843124.001]
  • [Cites] Mayo Clin Proc. 1980 Dec;55(12):747-53 [6261047.001]
  • [Cites] Am J Pathol. 1983 Feb;110(2):105-12 [6130702.001]
  • [Cites] Hum Pathol. 1989 Mar;20(3):281-7 [2542151.001]
  • [Cites] Gastrointest Endosc. 1992 Mar-Apr;38(2):130-5 [1568608.001]
  • [Cites] Surg Today. 1992;22(5):421-5 [1421863.001]
  • [Cites] Gastrointest Endosc. 1993 Jan-Feb;39(1):103-4 [8267696.001]
  • [Cites] Mod Pathol. 1993 Sep;6(5):516-20 [8248106.001]
  • [Cites] J Korean Med Sci. 1997 Jun;12(3):256-61 [9250925.001]
  • [Cites] Am J Gastroenterol. 1998 Jan;93(1):111-4 [9448188.001]
  • [Cites] Endoscopy. 1998 Nov;30(9):800-4 [9932762.001]
  • [Cites] Radiographics. 2004 Nov-Dec;24(6):1561-73 [15537965.001]
  • [Cites] Histopathology. 2005 Feb;46(2):153-7 [15693887.001]
  • [Cites] Arch Pathol Lab Med. 2005 Mar;129(3):338-47 [15737028.001]
  • [Cites] Onkologie. 2005 May;28(5):270-2 [15867484.001]
  • [Cites] Ann Surg Oncol. 2005 Nov;12(11):886-94 [16177864.001]
  • [Cites] Rev Gastroenterol Disord. 2006 Winter;6(1):1-12 [16520707.001]
  • [Cites] APMIS. 2006 Oct;114(10):712-9 [17004974.001]
  • [Cites] World J Gastroenterol. 2006 Dec 7;12(45):7326-8 [17143949.001]
  • [Cites] Am J Clin Pathol. 2007 Jan;127(1):103-13 [17145637.001]
  • [Cites] Lancet Oncol. 2007 Jan;8(1):55-62 [17196511.001]
  • [Cites] AJR Am J Roentgenol. 2000 Sep;175(3):795-800 [10954469.001]
  • [Cites] Cancer. 2000 Dec 1;89(11):2214-21 [11147591.001]
  • [Cites] Endoscopy. 2001 Jun;33(6):507-10 [11437044.001]
  • [Cites] J Gastrointest Surg. 2002 Jul-Aug;6(4):614-6 [12127129.001]
  • [Cites] Am J Dig Dis. 1968 Oct;13(10):868-73 [5303029.001]
  • (PMID = 17620117.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 32
  • [Other-IDs] NLM/ PMC1937002
  • [General-notes] NLM/ Original DateCompleted: 20070810
  •  go-up   go-down


5. Giigoruk OG, Lazarev AF, Doroshenko VS: [Pleural metastases of renal carcinoma]. Urologiia; 2007 Mar-Apr;(2):42-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pleural metastases of renal carcinoma].
  • Metastases in renal carcinoma are diagnosed at initial diagnosis in 25% examinees.
  • Traditional renal carcinoma has higher metastatic potential, is associated with worse survival of the patients compared to papillary cancer.
  • We studied cytological characteristics of renal carcinoma metastases to the pleura in comparison with histological studies of the primary lesion using immunohistochemical findings.
  • We examined cytologically pleural liquid in renal carcinoma metastases to the pleura in 6 patients (2.3% of carcinomatous pleuricies).
  • In 3 cases initial cancer was renal cell carcinoma, pleural exudation developed 2 years later, clear cell carcinoma appeared 6 years later and papillary cancer--10 years later.
  • In the other 3 cases malignant cells were detected in new-onset cases.
  • Cytological preparations were studied with identification of cytological signs typical for classic clear cell, granulocell and papillary renal cancer.
  • Immunohistochemical examination of primary tumor lesion in the kidney discovered high proliferative activity of tumor cells by Ki-67 index to 5.28%.
  • This is confirmed by renal carcinoma metastases to the pleura.
  • [MeSH-major] Carcinoma / secondary. Kidney Neoplasms / pathology. Pleural Neoplasms / diagnosis. Pleural Neoplasms / secondary
  • [MeSH-minor] Aged. Female. Humans. Ki-67 Antigen / analysis. Male. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / analysis. Receptor, ErbB-2 / analysis. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17578198.001).
  • [ISSN] 1728-2985
  • [Journal-full-title] Urologii︠a︡ (Moscow, Russia : 1999)
  • [ISO-abbreviation] Urologiia
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


6. Iankov ID, Msaouel P, Allen C, Federspiel MJ, Bulur PA, Dietz AB, Gastineau D, Ikeda Y, Ingle JN, Russell SJ, Galanis E: Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model. Breast Cancer Res Treat; 2010 Aug;122(3):745-54
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model.
  • Breast cancer is the second leading cause of malignant effusions in cancer patients.
  • Pleural effusion indicates incurable disease with limited palliative treatment options and poor outcome.
  • Here, we demonstrate the therapeutic efficacy of measles virus (MV) vaccine strain derivative against malignant pleural effusion in an MDA-MB-231 xenograft model of advanced breast cancer.
  • Both systemic intravenous (i.v.) and intrapleural (t.t.) administered virus caused massive infection and syncytia formation in the pleural tumor deposits.
  • Furthermore, we tested human dendritic cells as carriers for delivery of oncolytic MV infection to breast cancer pleural metastases.
  • Carrier-delivered MV infection prevented accumulation of the pleural exudate and also significantly improved the survival of the treated mice.
  • This is the first demonstration of the therapeutic potential of oncolytic virotherapy against malignant pleural effusions in a pre-clinical model of advanced breast cancer.

  • Genetic Alliance. consumer health - Measles.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Gene Ther. 2002 May 1;13(7):803-13 [11975847.001]
  • [Cites] Blood. 2001 Oct 1;98(7):2002-7 [11567982.001]
  • [Cites] N Engl J Med. 2002 Jun 20;346(25):1971-7 [12075059.001]
  • [Cites] Cancer Res. 2003 May 15;63(10):2462-9 [12750267.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4919-26 [15256464.001]
  • [Cites] Eur J Cardiothorac Surg. 2004 Aug;26(2):432-6 [15296910.001]
  • [Cites] J Infect Dis. 1990 Nov;162(5):1036-42 [2230231.001]
  • [Cites] Chest. 1997 Oct;112(4 Suppl):291S-295S [9337306.001]
  • [Cites] Diagn Microbiol Infect Dis. 1999 Mar;33(3):147-52 [10092962.001]
  • [Cites] Thorax. 1999 Aug;54(8):707-10 [10413724.001]
  • [Cites] J Virol. 1999 Nov;73(11):9568-75 [10516065.001]
  • [Cites] Chest. 2004 Nov;126(5):1529-39 [15539723.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2287-94 [15961518.001]
  • [Cites] Eur Respir J. 2006 Apr;27(4):817-21 [16585090.001]
  • [Cites] J Virol. 2006 Aug;80(15):7769-74 [16840358.001]
  • [Cites] Breast Cancer Res Treat. 2006 Sep;99(2):177-84 [16642271.001]
  • [Cites] Lung Cancer. 2006 Oct;54(1):1-9 [16893591.001]
  • [Cites] J Gen Virol. 2006 Oct;87(Pt 10):2767-79 [16963735.001]
  • [Cites] Mol Ther. 2007 Jan;15(1):114-22 [17164782.001]
  • [Cites] Transfusion. 2006 Dec;46(12):2083-9 [17176319.001]
  • [Cites] Mayo Clin Proc. 2008 Feb;83(2):235-50 [18241636.001]
  • [Cites] Eur J Intern Med. 2008 Jul;19(5):334-9 [18549935.001]
  • [Cites] Exp Oncol. 2008 Jun;30(2):91-5 [18566569.001]
  • [Cites] Clin Vaccine Immunol. 2008 Jul;15(7):1054-9 [18463223.001]
  • [Cites] Prostate. 2009 Jan 1;69(1):82-91 [18973133.001]
  • [Cites] Curr Top Microbiol Immunol. 2009;330:213-41 [19203112.001]
  • [Cites] Mol Ther. 2009 Aug;17(8):1395-403 [19471250.001]
  • [Cites] J Virol. 2000 Sep;74(17):7972-9 [10933705.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Sep 7;275(3):731-8 [10973791.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3746-54 [11389012.001]
  • [Cites] Nat Med. 2002 May;8(5):527-31 [11984600.001]
  • (PMID = 19894113.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA108961; United States / NCI NIH HHS / CA / P50 CA116201-010005; United States / NCI NIH HHS / CA / P50 CA116201; United States / NCI NIH HHS / CA / P50CA108961; United States / NCI NIH HHS / CA / CA116201-010005
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Measles Vaccine
  • [Other-IDs] NLM/ NIHMS228888; NLM/ PMC2935656
  •  go-up   go-down


7. Mizuta N, Sakaguchi K, Mizuta M, Ichida M, Ohashi M, Umeda Y, Nishiyama A, Matsumoto M, Fujiwara I: [Long-term complete response in a patient with breast cancer and bone and pleura metastases after treatment with a combination of S-1 and zoledronic acid]. Gan To Kagaku Ryoho; 2010 Jul;37(7):1317-20
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term complete response in a patient with breast cancer and bone and pleura metastases after treatment with a combination of S-1 and zoledronic acid].
  • We report a long-term complete response (CR) in a patient with postoperative recurrent breast cancer and bone and pleura metastases after treatment with a combination of S-1 and zoledronic acid.
  • However, combination therapy with S-1 and zoledronic acid was started because of the development of bone and pleura metastases.
  • After 3 cycles of treatment, the patient's tumor marker levels had decreased to normal values, and both the bone and pleura metastases had disappeared.
  • [MeSH-major] Bone Density Conservation Agents / therapeutic use. Bone Neoplasms / drug therapy. Breast Neoplasms / drug therapy. Diphosphonates / therapeutic use. Imidazoles / therapeutic use. Oxonic Acid / therapeutic use. Pleural Neoplasms / drug therapy. Tegafur / therapeutic use
  • [MeSH-minor] Biomarkers, Tumor / blood. Drug Combinations. Humans. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Bone Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20647717.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Drug Combinations; 0 / Imidazoles; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; 6XC1PAD3KF / zoledronic acid
  •  go-up   go-down


8. Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Grégoire M, Porte H, Copin MC, Lassalle P: Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res; 2007 May 15;13(10):2928-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
  • PURPOSE: Malignant mesothelioma is a highly aggressive tumor and is often diagnosed too late for a curative treatment.
  • We compared diagnostic and prognostic values of mesothelin and osteopontin in 172 patients suspected of malignant pleural mesothelioma (MPM) and in a control group of 112 asymptomatic asbestos-exposed subjects.
  • EXPERIMENTAL DESIGN: Osteopontin and mesothelin were assayed with commercial ELISA kits in a series of 43 patients with pleural metastases of various carcinomas, 33 patients with benign pleural lesions associated with asbestos exposure, 96 patients with MPMs, and 112 asbestos-exposed healthy subjects.
  • Results were correlated with patient's diagnosis and survival.
  • However, osteopontin was unable to distinguish between MPM and pleural metastatic carcinoma or benign pleural lesions associated with asbestos exposure.
  • Neither plasma nor pleural fluid osteopontin were more powerful in this respect.
  • Survival analysis identified tumor histologic subtype along with serum osteopontin and serum mesothelin as independent prognostic factors in mesothelioma patients.
  • [MeSH-major] Membrane Glycoproteins / blood. Mesothelioma / diagnosis. Osteopontin / blood. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Aged. Extracellular Fluid / chemistry. Female. GPI-Linked Proteins. Humans. Male. Middle Aged. Pleura / chemistry. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504993.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 106441-73-0 / Osteopontin
  •  go-up   go-down


9. Decroisette C, Melloni B, Moldovan D, Gazaille V, Fermeaux V, Bertin F, Bonnaud F: [Pleural metastases of sclerosing epithelioid fibrosarcoma]. Rev Pneumol Clin; 2006 Jun;62(3):179-82
Genetic Alliance. consumer health - Fibrosarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pleural metastases of sclerosing epithelioid fibrosarcoma].
  • [Transliterated title] Métastases pleurales d'un fibrosarcome épithélioïde sclérosant.
  • Sclerosing epithelioid fibrosarcoma is a rare tumor recently described.
  • Metastatic spread is usually late in the natural course of the disease.
  • We report a case of recurrent sclerosing epithelioid fibrosarcoma with pleural metastases which developed ten years after surgical resection of the primary tumor.
  • The tumor was formed by small uniform round epithelioid cells with a clear cytoplasm.
  • The tumor cells were strongly positive for vimentin.
  • [MeSH-major] Fibrosarcoma / secondary. Pleural Neoplasms / secondary. Soft Tissue Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16840996.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Vimentin
  •  go-up   go-down


10. Klee H, Vestring T, Bittmann I: [Pleural metastases of a typical bronchial carcinoid 7 years after lobectomy]. Pneumologie; 2008 Oct;62(10):607-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pleural metastases of a typical bronchial carcinoid 7 years after lobectomy].
  • [Transliterated title] Pleurales Rezidiv eines typischen pulmonalen Karzinoids 7 Jahre nach Operation.
  • BACKGROUND: Bronchial carcinoids are a rare differential diagnosis of solitary pulmonary nodes.
  • Typically metastases develop in the lung, liver, brain, bone and adrenal glands.
  • CASE REPORT: Seven years after lobectomy of a bronchial carcinoid, a slow-growing thickening of the pleura parietalis was noted in a 54-year-old male patient.
  • The histological diagnosis of pleural metastases was established via trans-thoracic punctation.
  • Pleural metastases of bronchial carcinoids are extremely rare.
  • Metastatic disease--as in the rare case of pleural metastases shown here--remains a therapeutic dilemma.
  • [MeSH-major] Bronchial Neoplasms / diagnosis. Bronchial Neoplasms / surgery. Pleural Neoplasms / diagnosis. Pleural Neoplasms / secondary
  • [MeSH-minor] Diagnosis, Differential. Humans. Lymphatic Metastasis. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18711695.001).
  • [ISSN] 1438-8790
  • [Journal-full-title] Pneumologie (Stuttgart, Germany)
  • [ISO-abbreviation] Pneumologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


11. Tatsuta M, Iishi H, Baba M, Uedo N, Ishihara R, Higashino K, Mukai M, Ishiguro S: Induction by lysophosphatidic acid of peritoneal and pleural metastases of intestinal cancers induced by azoxymethane in Wistar rats. Cancer Lett; 2005 Mar 10;219(2):137-45

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction by lysophosphatidic acid of peritoneal and pleural metastases of intestinal cancers induced by azoxymethane in Wistar rats.
  • The effects of 1-oleoyl lysophosphatidic acid on the induction of metastasis from intestinal adenocarcinomas induced in rats by azoxymethane and on RhoA activity in the tumors were investigated in male Wistar rats.
  • Lysophosphatidic acid at both dosages significantly increased the incidence of peritoneal metastasis.
  • Its administration at higher dosage also significantly enhanced the development of pleural metastasis.
  • Our findings indicate that lysophosphatidic acid significantly increased the incidence of peritoneal and/or pleural metastases from intestinal adenocarcinomas induced in rats by azoxymethane through RhoA activation.
  • [MeSH-major] Adenocarcinoma / secondary. Intestinal Neoplasms / chemically induced. Lysophospholipids / pharmacology. Peritoneal Neoplasms / secondary. Pleural Neoplasms / secondary. rhoA GTP-Binding Protein / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15723712.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Lysophospholipids; 0 / Proliferating Cell Nuclear Antigen; 22002-87-5 / lysophosphatidic acid; EC 3.6.5.2 / rhoA GTP-Binding Protein; MO0N1J0SEN / Azoxymethane
  •  go-up   go-down


12. Carillo GA, Carretero MA, Vazquez JE, Fontan EG, Ramos MB, Ventura JA, Rodriguez AP, Salmon AS, Tejedor JL: Epithelioid angiosarcoma of the lung with pleural metastases: a rare cause of haemoptysis clinicopathological conference. Heart Lung Circ; 2010 Oct;19(10):624-8
Hazardous Substances Data Bank. HEMATOXYLIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelioid angiosarcoma of the lung with pleural metastases: a rare cause of haemoptysis clinicopathological conference.
  • Angiosarcomas are a rare type of malignant vascular tumour characterised by proliferation of tumour cells with vascular endothelial features.
  • Pulmonary angiosarcomas are usually secondary tumours, and only a few primary cases have been reported.
  • We present a case of a 56 year-old male with persistent haemoptysis secondary to lung epithelioid angiosarcoma with pleural metastases.
  • [MeSH-major] Hemangiosarcoma / pathology. Hemoptysis / etiology. Lung Neoplasms / pathology. Pleural Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Australasian Society of Cardiac and Thoracic Surgeons and the Cardiac Society of Australia and New Zealand. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20541463.001).
  • [ISSN] 1444-2892
  • [Journal-full-title] Heart, lung & circulation
  • [ISO-abbreviation] Heart Lung Circ
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Coloring Agents; YKM8PY2Z55 / Hematoxylin
  •  go-up   go-down


13. Kościuch J, Zielonka TM, Ziółkowski B, Domagała-Kulawik J, Bogacka-Zatorska E, Chazan R: [Breast carcinoma and anaplastic gastric carcinoma with pleural metastases in patient after mastectomy 30 years ago]. Pneumonol Alergol Pol; 2006;74(1):129-31
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Breast carcinoma and anaplastic gastric carcinoma with pleural metastases in patient after mastectomy 30 years ago].
  • We describe a case of two simultaneous malignancies--anaplastic gastric carcinoma with pleural metastases and left breast carcinoma.
  • Her parents died from malignancies--mother from gastric cancer and father from pulmonary carcinoma.
  • One should remember that there is always possibility of simultaneous development of more than one primary malignancies in one patient and neoplastic disease is an important cancer risk factor.
  • This observation confirms the important role of genetic factors in the pathogenesis of malignant diseases.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma / pathology. Carcinoma / secondary. Neoplasms, Multiple Primary / pathology. Pleural Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Fatal Outcome. Female. Humans. Mastectomy, Radical. Neoplasm Recurrence, Local. Pedigree

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175993.001).
  • [ISSN] 0867-7077
  • [Journal-full-title] Pneumonologia i alergologia polska
  • [ISO-abbreviation] Pneumonol Alergol Pol
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


14. Piscitelli D, Sanguedolce F, Mattioli E, Parisi G, Fiore MG, Resta L: [Unusual presentation of metastatic osteosarcoma as a giant duodenal polyp. A case report]. Pathologica; 2005 Apr;97(2):88-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unusual presentation of metastatic osteosarcoma as a giant duodenal polyp. A case report].
  • [Transliterated title] Osteosarcoma metastatico polipoide del duodeno. descrizione di un caso ad insolita presentazione.
  • INTRODUCTION: Osteosarcoma is a malignant bone neoplasm with an usually high metastatic potential.
  • Besides the common metastatic sites such as lungs, bone, and pleura, metastases to unusual sites such as liver, brain and regional lymph nodes have also been reported with increasing frequency; among them, gastrointestinal metastases represent an extraordinarily rare event in the natural history of this neoplasia.
  • RESULTS: Microscopically, the tumor mass showed a mostly fasciculated architecture, composed of spindle and epithelioid cells in a scarce fibromyxoid stroma, featuring large areas of coagulative necrosis and small foci of sclerohyalinosis.
  • Tumor cells featured large vesciculous nuclei, with a few prominent nucleoli; no foci of osteoid matrix were detectable.
  • Due to alteration of the natural history of the tumor induced by multiagent chemotherapy, the rate of metastases of osteosarcoma to unusual sites has been increasing.
  • We report the 9th case of a gastrointestinal metastasis of osteosarcoma reported thus far, and only the second one arising in the duodenum.
  • Both the histological features and the immunohistochemical findings were not suggestive for osteosarcoma metastases because the tumor appeared dedifferentiated; in our case the combination of electron microscopy and clinical history played a pivotal role to establish the final diagnosis.
  • [MeSH-major] Bone Neoplasms / pathology. Duodenal Neoplasms / pathology. Duodenal Neoplasms / secondary. Osteosarcoma / secondary. Tibia

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16032954.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


15. Shao YY, Hong RL: Pleural metastases as a unique entity with dismal outcome of head and neck squamous cell carcinoma. Oral Oncol; 2010 Sep;46(9):694-7
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleural metastases as a unique entity with dismal outcome of head and neck squamous cell carcinoma.
  • Once distant metastasis occurs, head and neck squamous cell carcinoma (HNSCC) patients generally have a poor prognosis with limited treatment options.
  • A subgroup of patients who developed pleural metastases after curative treatment of localized HNSCC appeared to have worse outcomes.
  • All patients from National Taiwan University Hospital who were diagnosed with localized HNSCC from January 1, 2000 to December 31, 2007 and developed distant metastases were included in this analysis.
  • Patients with pleura as the first metastatic sites were compared to those with other first metastases for differences in basic demographics, time to distant metastasis (TTM) and overall survival (OS).
  • A total of 198 patients were included, and 52 (26%) had pleural involvement at first diagnosis of distant metastases.
  • Younger age at diagnosis (P=0.002) and buccal mucosa origin (P=0.006) were risk factors for developing pleural metastases.
  • Patients with pleura as the first metastatic sites, compared to those with other first metastases, had significantly shorter TTM (median 7.5 vs. 11.1 months, P<0.001) and OS (median 9.6 vs. 16.5 months, P<0.001).
  • By multivariate analysis, pleural metastases remained an independent predictor for shorter OS.
  • In conclusion, patients with pleural metastases comprise a unique subgroup of HNSCC which rapidly develop distant metastases with poor prognosis.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Head and Neck Neoplasms / pathology. Pleural Neoplasms / secondary
  • [MeSH-minor] Female. Humans. Lymphatic Metastasis. Male. Medical Records. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Taiwan

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20739213.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


16. Khadse P, Prabhash K, Pramesh CS, Chaturvedi P, Shet T: Fine-needle aspiration biopsy of pleural metastases from a carcinosarcoma or true malignant mixed tumor of the parotid gland mimicking a mesothelioma. Diagn Cytopathol; 2009 Sep;37(9):680-5
Hazardous Substances Data Bank. GUANINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration biopsy of pleural metastases from a carcinosarcoma or true malignant mixed tumor of the parotid gland mimicking a mesothelioma.
  • Malignant mixed tumor of the parotid is known to have odd sites for metastases.
  • We describe the fine-needle aspiration cytology (FNAC) findings of pleural metastasis from a malignant mixed tumor misdiagnosed as a mesothelioma on cytology at the onset.A 47-year-old man presented to us with breathlessness and a massive pleural effusion with pleural-based nodules.
  • FNAC from the pleural lesions showed myxoid background substance with entrapped cuboidal epithelial cells with atypical nuclei, which were interpreted as mesothelial cells.
  • These cells in contrast to the usual mesothelial cells were not arranged in sheets but rather were huddled in places and formed a pseudoacinar pattern and blended with the myxoid substance.After the diagnosis of a mesothelioma, patient received pemetrexed and cisplatin based chemotherapy with partial response.
  • While on chemotherapy tumor recurred at the primary site in parotid and was confirmed to be a carcinosarcoma on a FNAC and biopsy.To conclude, pleural metastases from a true malignant mixed tumor of the parotid gland can be misdiagnosed as mesothelioma and could occur in the absence of uncontrolled disease at primary site.
  • Both mesotheliomas and pleomorphic adenomas metastatic to the pleura are biphasic tumors, but in a patient with history of pleomorphic adenoma, the latter should be kept as a foremost possibility.
  • Attention to the cytomorphology of tumor cells will also assist in confirming the diagnosis.
  • [MeSH-major] Carcinosarcoma / secondary. Mesothelioma / pathology. Neoplasms, Complex and Mixed / secondary. Parotid Neoplasms / pathology. Pleural Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Fine-Needle. Cisplatin / administration & dosage. Diagnosis, Differential. Diagnostic Errors. Glutamates / administration & dosage. Guanine / administration & dosage. Guanine / analogs & derivatives. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Pemetrexed. Pleural Effusion, Malignant / etiology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Wiley-Liss, Inc.
  • (PMID = 19373913.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


17. Sugarbaker DJ, Tilleman TR, Swanson SJ, Jaklitsch MT, Mentzer SJ, Mujoomdar AA, Bueno R: The role of extrapleural pneumonectomy in the management of pleural cancers. J Clin Oncol; 2009 May 20;27(15_suppl):7577

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of extrapleural pneumonectomy in the management of pleural cancers.
  • For all cases, the site of disease involved a single pleura.
  • Of these, 32 patients had mediastinoscopy negative T4 lung cancer, 11 had metastases to only one pleura from extrathoracic sites, 10 had unilateral lung sarcomas involving the pleural envelope, 8 had thymomas metastatic to a pleural space, 2 were preoperatively diagnosed as mesotheliomas but at final pathology were determined to be small cell lung cancer and sarcomatoid carcinoma, and 2 represented primary mucoepidermoid and neuroectodermal malignancies.
  • Median survival for patients with sarcoma (n=10) or pleural metastases from extrathoracic sites (n=11) was 3.7 and 4.2 months, respectively.
  • CONCLUSIONS: EPP can be a safe treatment option for some cancers that involve a unilateral pleura.
  • Patients with stage IIIB (T4, N0-1) NSCLC confined to a single pleural cavity or patients with thymoma involving one pleura may benefit from multimodality treatment including EPP.
  • Patients undergoing surgical resection for pleural metastases of primary sarcomas or extrathoracic metastasis, however, do not appear to benefit from EPP.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963385.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Verbeke N, Verstraete K, Sys G, Forsyth R, Kluyskens D, Denys H, Uyttendaele D, Rottey S: Osteosarcoma with extensive calcified pleural metastases at diagnosis. Acta Clin Belg; 2008 Sep-Oct;63(5):325-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma with extensive calcified pleural metastases at diagnosis.
  • Imaging of the lungs revealed pleural effusion and calcification of the left pleura.
  • An osteosarcoma of the left humerus was the final diagnosis.
  • A review of the literature reveals that calcified pleural metastatic disease in cases of osteosarcoma has been infrequently reported.
  • Other causes of pleural calcification are briefly discussed.
  • [MeSH-major] Bone Neoplasms / pathology. Humerus. Osteosarcoma / secondary. Pleural Neoplasms / secondary
  • [MeSH-minor] Adolescent. Calcinosis / etiology. Calcinosis / radiography. Fatal Outcome. Female. Humans. Lung Neoplasms / secondary. Pleural Effusion, Malignant / etiology. Pleural Effusion, Malignant / radiography. Respiratory Insufficiency / etiology. Shoulder Pain / etiology

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19186565.001).
  • [ISSN] 1784-3286
  • [Journal-full-title] Acta clinica Belgica
  • [ISO-abbreviation] Acta Clin Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


19. Mori T, Yoshioka M, Iwatani K, Kobayashi H, Yoshimoto K, Nomori H: Kissing pleural metastases from metastatic osteosarcoma of the lung. Ann Thorac Cardiovasc Surg; 2006 Apr;12(2):129-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Kissing pleural metastases from metastatic osteosarcoma of the lung.
  • Two patients with osteosarcoma lung metastases of which migrated to the parietal pleura due to contact are reported.
  • The first patient was a 16-year-old male who had a pleural metastasis in the diaphragm within an area in contact with a single lung metastasis.
  • Nine months after the resection of the first metastases, two other lung metastases were found which were resected after chemotherapy.
  • The patient is alive without recurrence 84 months after the first resection of the metastases.
  • The second patient was an 11-year-old female with a pleural metastasis of osteosarcoma which was within an area in contact with a single lung metastasis, which had been resected 4 months before.
  • We concluded (1) that a lung metastasis of osteosarcoma occasionally metastasizes to the pleura due to contact; and (2) that because this kissing metastases of osteosarcoma could be cured by a complete resection, the intrathoracic cavity should be thoroughly observed.
  • [MeSH-major] Bone Neoplasms / pathology. Lung Neoplasms / secondary. Osteosarcoma / pathology. Pleural Neoplasms / secondary
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Child. Female. Femur / pathology. Humans. Male. Neoplasm Metastasis. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702936.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


20. Andre F, Cabioglu N, Assi H, Sabourin JC, Delaloge S, Sahin A, Broglio K, Spano JP, Combadiere C, Bucana C, Soria JC, Cristofanilli M: Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer. Ann Oncol; 2006 Jun;17(6):945-51
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of chemokine receptors predicts the site of metastatic relapse in patients with axillary node positive primary breast cancer.
  • BACKGROUND: Recent studies have suggested that chemokine receptors are involved in development of organ-specific pattern of metastases.
  • In the present study, we evaluated the association between the chemokine receptors expressed in primary tumor cells and the site of metastatic relapse in patients with breast cancer.
  • METHODS: Primary tumors were obtained from 142 patients with axillary node-positive breast cancer and stained for CX3CR1, CXCR4, CCR6, and CCR7 expression.
  • By estimating the Mantel-Haenszel odds ratios (OR), CXCR4 was associated with increased risk of metastasis to the liver (OR = 3.71, P = 0.005), CX3CR1 was associated with metastasis to the brain (OR = 13.18, P = 0.01).
  • Patients with CCR6 positivity were more likely to develop a first metastasis in the pleura (OR = 2.82, P = 0.06).
  • In addition, CCR7 expression was associated with the occurrence of skin metastases (11% versus 0%, P = 0.017).
  • INTERPRETATION: Expression of chemokine receptors in the primary tumor predicts the site of metastatic relapse in patients with axillary node positive breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16627550.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Receptors, Chemokine; 0 / Receptors, Estrogen; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


21. Yildirim H, Metintaş M, Ak G, Dündar E, Erginel S: Soft tissue sarcoma metastatic to pleura. Tuberk Toraks; 2008;56(2):197-200
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue sarcoma metastatic to pleura.
  • Almost all cancers can cause distant pleural metastases.
  • However, pleural metastases of soft tissue sarcoma that constitute less than 1% of adult solid malignancy are extremely rare.
  • It is very difficult to distinguish them form sarcomatous malignant mesothelioma on histopathological features.
  • We report a 57 year-old man who presented to us with left chest pain and progressive dyspnea and was diagnosed to have a pleural metastases of soft tissue sarcoma by thoracoscopic biopsy.
  • [MeSH-major] Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Sarcoma / pathology. Thoracoscopy / methods
  • [MeSH-minor] Diagnosis, Differential. Fatal Outcome. Humans. Male. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Tuberk Toraks. 2008;56(4):487-8; author reply 488 [19123090.001]
  • [CommentIn] Tuberk Toraks. 2008;56(4):485; author reply 486 [19123089.001]
  • (PMID = 18701980.001).
  • [ISSN] 0494-1373
  • [Journal-full-title] Tüberküloz ve toraks
  • [ISO-abbreviation] Tuberk Toraks
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


22. Ohnishi H, Abe M, Hamada H, Yokoyama A, Hirayama T, Ito R, Nishimura K, Higaki J: Metastatic renal cell carcinoma presenting as multiple pleural tumours. Respirology; 2005 Jan;10(1):128-31
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic renal cell carcinoma presenting as multiple pleural tumours.
  • Chest X-ray and chest computed tomography (CT) demonstrated a left-sided pleural effusion and multiple tumours, suggesting malignant mesothelioma in the left pleural space, but there were no pulmonary lesions.
  • However, abdominal CT revealed a right renal tumour.
  • An ultrasonography-guided needle biopsy of the pleural mass provided evidence of metastatic renal cell carcinoma (RCC).
  • The pleural lesions dramatically decreased in size following right radical nephrectomy and subsequent interferon-alpha treatment.
  • While the thorax is a frequently affected site of RCC, sole pleural metastases are rare and are often secondary to lung involvement.
  • Batson's plexus, a network of vertebral valve-less veins with multiple connections, is likely responsible for the contralateral pleural metastases of RCC.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Kidney Neoplasms / pathology. Pleural Neoplasms / secondary
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Male. Mesothelioma / diagnosis. Pleural Effusion, Malignant / pathology

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15691252.001).
  • [ISSN] 1323-7799
  • [Journal-full-title] Respirology (Carlton, Vic.)
  • [ISO-abbreviation] Respirology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


23. Wilcox BE, Subramaniam RM, Peller PJ, Aughenbaugh GL, Nichols Iii FC, Aubry MC, Jett JR: Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma. Clin Lung Cancer; 2009 Jul;10(4):244-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma.
  • BACKGROUND: Malignant pleural mesothelioma (MPM) is a primary malignancy characterized by local invasion of the pleura and metastasis.
  • MATERIALS AND METHODS: Mayo Clinic databases were queried to identify cases with a histologic diagnosis of MPM from 2000 to 2006.
  • Inclusion criteria were a diagnosis of MPM, an available CT scan, and an initial staging integrated CT-PET scan.
  • A total of 35 patients were identified who met the inclusion criteria.
  • The Mayo Clinic tumor registry and Social Security database were queried for survival data in patients in which no follow-up was available.
  • CONCLUSION: Malignant pleural mesothelioma is a difficult disease to accurately stage.
  • The most common reason for upstaging in our series was an increase in T (tumor; tumor-node-metastasis staging system) disease.
  • Our data suggest that integrated CT-PET is excellent for detecting nodal and distant metastases.
  • [MeSH-major] Mesothelioma / radionuclide imaging. Pleural Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Female. Fluorodeoxyglucose F18. Humans. Male. Middle Aged. Neoplasm Staging / methods. Radiopharmaceuticals. Retrospective Studies. Sensitivity and Specificity


24. Cohen-Mouly S, Badia A, Bats AS, Barthes F, Bensaïd C, Riquet M, Lécuru F: Role of video-assisted thoracoscopy in patients with ovarian cancer and pleural effusion. Int J Gynecol Cancer; 2009 Dec;19(9):1662-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of video-assisted thoracoscopy in patients with ovarian cancer and pleural effusion.
  • OBJECTIVES: To evaluate the feasibility of video-assisted thoracoscopy (VAT) for staging advanced ovarian cancer, to measure the performance of preoperative computed tomography (CT) for diagnosing pleural metastases, to assess the correlation between pleural and abdominal involvement, and to measure the impact of VAT on patient management.
  • METHODS: We retrospectively evaluated 16 VAT procedures in 15 patients with advanced ovarian malignancies and pleural effusions.
  • The reason for VAT was either to evaluate unilateral or bilateral pleural effusions (n = 15) or to evaluate pleural metastases after neoadjuvant chemotherapy (n = 1).
  • The rates of involvement of the hepatic pedicle, mesentery, and right side of the diaphragm were compared with the rate of pleural involvement.
  • Video-assisted thoracoscopy identified metastases smaller than 1 cm in 5 patients and larger than 1 cm in 2 additional patients; there was no evidence of pleural involvement in 6 patients.
  • Computed tomography had 14% sensitivity and 25% specificity for pleural status determination, using VAT biopsy as the reference standard.
  • Pleural involvement did not correlate with involvement of the hepatic pedicle, mesentery, or right side of the diaphragm.
  • CONCLUSIONS: Video-assisted thoracoscopy performs better than CT for evaluating pleural involvement in ovarian cancer.
  • [MeSH-major] Carcinoma / surgery. Ovarian Neoplasms / surgery. Pleural Effusion, Malignant / diagnosis. Thoracic Surgery, Video-Assisted
  • [MeSH-minor] Aged. Biopsy, Needle. Disease Progression. Feasibility Studies. Female. Humans. Middle Aged. Neoplasm Staging / methods. Pleural Neoplasms / diagnosis. Pleural Neoplasms / secondary. Pleural Neoplasms / surgery. Retrospective Studies. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19955956.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Grigoriu B, Chahine B, Zerimech F, Grégoire M, Balduyck M, Copin MC, Devos P, Lassalle P, Scherpereel A: Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. Clin Biochem; 2009 Jul;42(10-11):1046-50
Hazardous Substances Data Bank. HYALURONIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma.
  • We assessed comparatively the diagnostic value of two potential malignant pleural mesothelioma (MPM) markers: hyaluronic acid (HA) and soluble mesothelin.
  • MATERIALS AND METHOD: We measured serum and pleural fluid values of mesothelin and hyaluronic acid in 76 patients with MPM, 33 patients with pleural metastases of carcinomas (Mets group) and 27 patients with benign pleural effusion related to asbestos exposure (BPLAE).
  • In pleural fluid, both markers had similar diagnostic values.
  • [MeSH-major] Hyaluronic Acid / blood. Membrane Glycoproteins / blood. Mesothelioma / blood. Mesothelioma / diagnosis
  • [MeSH-minor] Aged. Female. GPI-Linked Proteins. Humans. Male. Pleural Effusion / blood

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • HAL archives ouvertes. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19302997.001).
  • [ISSN] 1873-2933
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


26. Schinstine M, Abati A, Tsokos M, Fox E, Filie AC: Cytological identification of metastatic epithelial nephroblastoma in pleural fluid: report of a case and review of literature. Diagn Cytopathol; 2006 Sep;34(9):621-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytological identification of metastatic epithelial nephroblastoma in pleural fluid: report of a case and review of literature.
  • Nephroblastoma (Wilms' tumor) is the most common childhood renal tumor and usually presents with a histology and cytology consisting of blastemal, epithelial, and stromal cells.
  • Effusions are not uncommon and may suggest an unfavorable prognosis when containing anaplastic tumor cells.
  • In the present case, we report the cytological appearance of a Wilms' tumor metastatic to the pleura.
  • The effusion consisted primarily of tumor cells demonstrating epithelial differentiation.
  • The tumor cells mostly presented as three-dimensional aggregates in an inflammatory background.
  • The tumor cells demonstrated strong CD56 and WT1 immunoreactivity.
  • [MeSH-major] Cytodiagnosis / methods. Kidney Neoplasms / pathology. Pleural Effusion, Malignant / pathology. Pleural Neoplasms / secondary. Wilms Tumor / secondary
  • [MeSH-minor] Antigens, CD56 / analysis. Biomarkers, Tumor / analysis. Carrier Proteins / analysis. Child. DNA-Binding Proteins / analysis. Fatal Outcome. Humans. Male. Nuclear Proteins / analysis

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16900470.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD56; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / WTAP protein, human
  •  go-up   go-down


27. Kim TJ, Lee KH, Kim YH, Sung SW, Jheon S, Cho SK, Lee KW: Postoperative imaging of esophageal cancer: what chest radiologists need to know. Radiographics; 2007 Mar-Apr;27(2):409-29
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative imaging of esophageal cancer: what chest radiologists need to know.
  • A variety of surgical procedures are used in the treatment of esophageal cancer.
  • Although meticulous surgical techniques and improved postoperative care have markedly reduced the complications associated with these techniques, esophageal resection is still associated with various intraoperative complications (hemorrhage, injury to the tracheobronchial tree, recurrent laryngeal nerve injury) and postoperative complications (anastomotic leak; mediastinitis; respiratory problems, including pleural effusion, pneumonia, and acute respiratory distress syndrome; cardiac and functional complications).
  • Postoperative tumor recurrence is not uncommon in patients undergoing curative resection for esophageal cancer and can be categorized as either locoregional (locoregional lymph node metastases, anastomotic recurrence) or distant (hematogenous metastases, pleural or peritoneal seeding).
  • Hematogenous metastases most commonly involve the liver, lungs, and bones, followed by the adrenal glands, brain, and kidneys.
  • Hematogenous metastases may also involve multiple organs simultaneously.
  • The radiologist must understand how these procedures can affect imaging data and be familiar with the appearances of postoperative anatomic changes, complications, and tumor recurrence to ensure accurate evaluation of affected patients.
  • [MeSH-major] Esophageal Neoplasms / radiography. Esophageal Neoplasms / surgery. Esophagectomy / adverse effects. Hemorrhage / radiography. Neoplasm Recurrence, Local / prevention & control. Neoplasm Recurrence, Local / radiography. Radiography, Thoracic / methods

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) RSNA, 2007.
  • (PMID = 17374861.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 77
  •  go-up   go-down


28. Brauner M, Brillet PY: [Other malignant tumors of the pleura]. Rev Pneumol Clin; 2006 Apr;62(2):124-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Other malignant tumors of the pleura].
  • [Transliterated title] Autres tumeurs pleurales malignes.
  • Malignant tumors of the pleura are most often diffuse, nethertheless they are sometimes localized.
  • There is an overlap of the radiologic features of the benign and malignant pleural lesions.
  • The differential diagnosis may be difficult, even on histological sample.
  • Imaging allows the diagnosis of pleural involvement, suggests the malignity, guides percutaneous or thoracoscopic biopsies of the pleura, defines extent of the tumor and follows the course of the disease.
  • We will describe the malignant pleural tumors: pleural metastases, pleural involvement of broncho-pulmonary cancer, of lymphoma and leukaemia.
  • Then the rare pleural tumors will be described: malignant pleural fibroma, sarcoma, histiocytoma and hemangiopericytoma.
  • [MeSH-major] Pleural Neoplasms / pathology. Pleural Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16670666.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 12
  •  go-up   go-down


29. Debevec L, Erzen J, Debeljak A, Crnjac A, Kovac V: Exploratory thoracotomy and its influence on the survival of patients with lung cancer. Wien Klin Wochenschr; 2006 Aug;118(15-16):479-84
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exploratory thoracotomy and its influence on the survival of patients with lung cancer.
  • PURPOSE: To evaluate diagnostic procedures, reasons for exploratory thoracotomy (ET), causes of unresectability of lung cancer, possibility for reducing numbers of ETs, and the influence of ET on survival.
  • PATIENTS AND METHODS: Between 1990 and 1999, 1808 patients with lung cancer were operated on.
  • The clinical stages were: three patients in stage IA, 28 in IB, one in IIA, 35 in IIB, 50 in IIIA, 10 in IIIB (all due to invasion of the mediastinum), and four patients in IV (three with ipsilateral pulmonary and one with solitary suprarenal metastasis).
  • The reasons for ET were: diagnosis of preoperatively unverified tumor in one patient, necessity for pneumonectomy in the case of poor pulmonary function in 11 patients, and unresectability in 119 (due to invasion of the mediastinum in 98 patients, thoracic wall in three and vertebral body in one, and due to pleural metastases in 17 patients).
  • [MeSH-minor] Adrenal Gland Neoplasms / secondary. Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Female. Humans. Lung / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Radiography, Thoracic. Survival Analysis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16957979.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


30. Maruyama S, Ito M, Hirano Y, Shimo T, Hashida S, Iga K, Inukai M, Kanaya Y, Yokoyama N: [A case of recurrent breast cancer with multiple lung metastases responding to anastrozole monotherapy]. Gan To Kagaku Ryoho; 2008 Oct;35(10):1787-9
Hazardous Substances Data Bank. ANASTROZOLE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of recurrent breast cancer with multiple lung metastases responding to anastrozole monotherapy].
  • A 51-year-old postmenopausal woman was referred to our hospital for treatment of ER-positive recurrent breast cancer.
  • The patient had lung and pleural metastases with pleural effusion from breast cancer.
  • The efficacy of the treatment was definite: the multiple metastatic lung lesions showed a partial response after 5 months' treatment, and reached a complete response after 14 months' treatment.
  • Anastrozole therapy is a useful treatment for postmenopausal woman with ER-positive recurrent breast cancer.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Neoplasm Recurrence, Local / drug therapy. Nitriles / therapeutic use. Triazoles / therapeutic use
  • [MeSH-minor] Biomarkers, Tumor / blood. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18931590.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nitriles; 0 / Triazoles; 2Z07MYW1AZ / anastrozole
  •  go-up   go-down


31. Nagoshi N, Anazawa U, Morioka H, Mukai M, Yabe H, Toyama Y: Epithelioid sarcoma arising on the forearm of a 6-year-old boy: case report and review of the literature. Pediatr Surg Int; 2006 Sep;22(9):771-3
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epithelioid sarcoma is a rare malignant tumor that occurs mainly in young adults and most frequently involves the distal portion of the upper extremities.
  • The tumor is particularly rare in children and more frequently involves the head and neck; only one case involving the forearm has been reported in a child under 10 years of age, and he was treated with amputation.
  • Two years later, no local recurrence was evident but pleural metastases were detected.
  • [MeSH-minor] Humans. Magnetic Resonance Imaging. Neoplasm, Residual. Reoperation. Skin Transplantation

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16786373.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 13
  •  go-up   go-down


32. Duysinx BC, Larock MP, Nguyen D, Corhay JL, Bury T, Hustinx R, Louis R: 18F-FDG PET imaging in assessing exudative pleural effusions. Nucl Med Commun; 2006 Dec;27(12):971-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FDG PET imaging in assessing exudative pleural effusions.
  • BACKGROUND: This study evaluates the accuracy of [F]fluorodeoxyglucose positron emission tomography (F-FDG PET) imaging with semi-quantitative analysis for differentiating benign from malignant pleural exudates and for guiding the search for the primary tumour of pleural metastases.
  • Thoracoscopy was systematically performed to reveal pathological diagnosis.
  • RESULTS: All SUVs were significantly higher in all malignant pleural diseases (n = 51) than in benign (n = 28) (P < 0.001).
  • Moreover SUVs were greater in the pleural metastases from pulmonary primaries (n = 25) and in mesotheliomas (n = 8) than in extrathoracic primaries (n = 18) (P < 0.01) with no significant difference between lung cancers and mesotheliomas.
  • Receiver operating curve (ROC) analysis between benign and malignant lesions showed areas under the curves that ranged from 0.803 (SUVbsa g) to 0.863 (SUVbw).
  • CONCLUSION: Semi-quantitative analysis of 18F-FDG PET imaging helps to differentiate malignant from benign pleural exudates and to distinguish between thoracic or extrathoracic primaries.
  • [MeSH-major] Exudates and Transudates / radionuclide imaging. Fluorodeoxyglucose F18. Pleural Effusion / radionuclide imaging. Pleural Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17088683.001).
  • [ISSN] 0143-3636
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


33. Mito K, Kashima K, Daa T, Kondoh Y, Miura T, Kawahara K, Nakayama I, Yokoyama S: Multiple calcifying fibrous tumors of the pleura. Virchows Arch; 2005 Jan;446(1):78-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple calcifying fibrous tumors of the pleura.
  • Calcifying fibrous tumor (CFT) is a rare lesion characterized histologically by hypocellular hyalinized collagenous tissue with psammomatous and/or dystrophic calcifications and patchy lymphoplasmacytic infiltrates.
  • CFT usually occurs in the somatic soft tissue of children and young adults but is rarely found in the pleura.
  • We describe here an unusual case of multiple small CFTs in the right mediastinal pleura of a 54-year-old man who had a history of renal cell carcinoma.
  • Suspecting pulmonary and pleural metastases, we performed wedge resection of the right middle lobe and local excision of two nodules in the right pleura.
  • Light microscopy revealed metastatic lesions of renal cell carcinoma in the resected wedge.
  • The pleural nodules were well circumscribed and composed of hypocellular, dense, hyalinized, collagenous tissue with scant lymphoplasmacytic infiltration and characteristic psammoma bodies.
  • We made a histological diagnosis of CFT of the pleura, and the patient remains well 6 months after the wedge resection.
  • [MeSH-major] Calcinosis / pathology. Pleural Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15660285.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 21
  •  go-up   go-down


34. Casal RF, Eapen GA, Morice RC, Jimenez CA: Medical thoracoscopy. Curr Opin Pulm Med; 2009 Jul;15(4):313-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RECENT FINDINGS: Recent data confirm the high diagnostic yield of medical thoracoscopy - both with rigid and semirigid instruments - in detecting pleural metastases and determining the origin of pleural effusions.
  • The degree of pleural adhesions found during thoracoscopy has been proposed by some authors as a prognostic factor for survival in patients with malignant pleural effusion.
  • SUMMARY: Medical thoracoscopy is an excellent tool to establish diagnosis in patients with exudative pleural effusion of unclear origin.
  • It is highly valuable in clarifying the origin of pleural effusions in patients with lung cancer, as the presence of a malignant pleural effusion is associated with poor survival and precludes the possibility of treatment with curative intention.
  • [MeSH-minor] Humans. Pleural Effusion / diagnosis. Pleural Effusion, Malignant / diagnosis. Pleurodesis / instrumentation. Pleurodesis / methods. Pleurodesis / trends. Prognosis. Thoracic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19387349.001).
  • [ISSN] 1531-6971
  • [Journal-full-title] Current opinion in pulmonary medicine
  • [ISO-abbreviation] Curr Opin Pulm Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 92
  •  go-up   go-down


35. Iwata T, Nishiyama N, Izumi N, Tsukioka T, Suehiro S: Metastatic monophasic synovial sarcoma of the pleura. Ann Thorac Cardiovasc Surg; 2007 Aug;13(4):258-61
Genetic Alliance. consumer health - Synovial sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic monophasic synovial sarcoma of the pleura.
  • Pleural metastasis of synovial sarcoma that originally developed in the soft tissue is a very rare entity.
  • A soft flat red tumor approximately 2 cm in diameter was shown on the pleura of the lingula, mimicking a blood clot on the pleura.
  • The tumor was removed by partial resection of the lung.
  • The mass lay in the pleura and did not seem to invade the lung parenchyma macroscopically.
  • Intraoperative frozen sectioning evidenced metastatic synovial sarcoma.
  • Many small patchy red lesions were also found on the visceral pleura of the lung and parietal pleura of the diaphragm.
  • We diagnosed unresectable pleural metastases of synovial sarcoma and finished the operation after sampling another pulmonary pleural lesion.
  • Postoperative histopathological examination revealed a solid and bundle-like proliferation of a short spindle cell tumor with a monophasic pattern, which was diagnosed as a metastatic pleural synovial sarcoma.
  • [MeSH-major] Muscle Neoplasms / pathology. Pleural Neoplasms / secondary. Sarcoma, Synovial / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17717503.001).
  • [ISSN] 1341-1098
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


36. Amin RM, Hiroshima K, Kokubo T, Nishikawa M, Narita M, Kuroki M, Nakatani Y: Risk factors and independent predictors of survival in patients with pulmonary epithelioid haemangioendothelioma. Review of the literature and a case report. Respirology; 2006 Nov;11(6):818-25
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pulmonary epithelioid haemangioendothelioma (PEH) is a rare pulmonary neoplasm.
  • A patient with PEH with lymph node and pleural metastases that were discovered incidentally is described.
  • Transbronchial lung biopsy did not provide a diagnosis.
  • The histological diagnosis of PEH was confirmed immunohistochemically by positive reactions to factor VIII-related antigen and CD34.
  • It revealed that male, symptomatic patients, presence of cough, haemoptysis, chest pain, multiple unilateral nodules, pleural effusion, metastases to more than one site and lymph node metastases were all significant risk factors for PEH (P<0.05).
  • Symptomatic patients and presence of pleural effusion were the independent predictors of survival in patients with PEH.
  • [MeSH-major] Hemangioendothelioma, Epithelioid / diagnosis. Hemangioendothelioma, Epithelioid / mortality. Lung Neoplasms / diagnosis. Lung Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17052315.001).
  • [ISSN] 1323-7799
  • [Journal-full-title] Respirology (Carlton, Vic.)
  • [ISO-abbreviation] Respirology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antigens, CD44; 0 / von Willebrand Factor
  • [Number-of-references] 69
  •  go-up   go-down


37. Rachid H, El Biaze M, Yassine N, Loudadsi F, Bakhatar A, Alaoui-Yazidi A, El Meziane A, Bahlaoui A: [Mediastinal paraganglioma with pleural metastasis. A case report]. Rev Pneumol Clin; 2005 Oct;61(5 Pt 1):315-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mediastinal paraganglioma with pleural metastasis. A case report].
  • Paraganglioma is rare tumor arising from chromaffine cells.
  • Surgical removal of this vascularized and invasive tumor was not possible to.
  • CT findings showed right nodular pleural masses.
  • This observation confirmed the rare course of paraganglioma to pleural metastases.
  • [MeSH-major] Mediastinal Neoplasms / pathology. Paraganglioma / secondary. Pleural Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292158.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


38. Sakai T, Kimura D, Hatanaka R, Yamada Y, Tsushima T, Fukuda I, Kamata Y: [Surgical treated pulmonary metastasis from prostatic cancer; report of a case]. Kyobu Geka; 2010 Apr;63(4):340-3
MedlinePlus Health Information. consumer health - Prostate Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treated pulmonary metastasis from prostatic cancer; report of a case].
  • A 74-year-old man who had been treated by endocrine therapy for prostatic cancer for 7 years was pointed out an abnormal shadow on the chest X-ray.
  • Computed tomography showed solitary tumor in the lower lobe of the left lung.
  • Transbronchial lung biopsy revealed pulmonary metastasis form prostatic cancer.
  • Because no other metastatic lesions were detected, the patient underwent surgery for pulmonary lesion.
  • Microscopically, the diagnosis of pulmonary and multiple pleural metastases was established.
  • The pulmonary metastasis without bone nor lymph node metastasis is rare.
  • Pleural metastasis should be considered in case of pulmonary metastasis from prostatic cancer.
  • Surgical indication for pulmonary metastasis from prostatic cancer has to be decided carefully.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / secondary. Pleural Neoplasms / secondary. Prostatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20387512.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


39. Okereke IC, Kesler KA, Morad MH, Mi D, Rieger KM, Birdas TJ, Badve S, Henley JD, Turrentine MW, Nelson RP, Loehrer PJ: Prognostic indicators after surgery for thymoma. Ann Thorac Surg; 2010 Apr;89(4):1071-7; discussion 1077-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSIONS: Long-term disease-specific survival can be expected not only after surgery for early stage thymoma but also after surgery for advanced disease, including patients with pleural metastases.
  • Late mortality due to secondary cancers and associated immunologic disorders was more frequent than mortality from thymoma in this series.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Time Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20338309.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


40. Isobe M, Eikawa S, Uenaka A, Nakamura Y, Kanda T, Kohno S, Kuzushima K, Nakayama E: Correlation of high and decreased NY-ESO-1 immunity to spontaneous regression and subsequent recurrence in a lung cancer patient. Cancer Immun; 2009;9:8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of high and decreased NY-ESO-1 immunity to spontaneous regression and subsequent recurrence in a lung cancer patient.
  • An integrated immune response consisting of IgG antibody, as well as CD4 and CD8 T cells, against NY-ESO-1 was observed at the time of spontaneous regression of multiple pleural metastases.
  • After tumor dormancy for 3 years, the tumor started to progress.
  • The findings suggest the relevance of the NY-ESO-1 immune response and its regulation by Foxp3+ CD25 high T regulatory cells in the clinical course of this lung cancer patient.
  • [MeSH-major] Adenocarcinoma / immunology. Antigens, Neoplasm / immunology. Immunity. Lung Neoplasms / immunology. Membrane Proteins / immunology. Neoplasm Regression, Spontaneous / immunology. Pleural Neoplasms / immunology
  • [MeSH-minor] Aged. CD4-Positive T-Lymphocytes / immunology. CD4-Positive T-Lymphocytes / metabolism. CD4-Positive T-Lymphocytes / pathology. CD8-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / metabolism. CD8-Positive T-Lymphocytes / pathology. Epitopes. Forkhead Transcription Factors / biosynthesis. Humans. Immunoglobulin G / metabolism. Interleukin-2 Receptor alpha Subunit / biosynthesis. Male. Neoplasm Recurrence, Local. T-Cell Antigen Receptor Specificity. T-Lymphocytes, Regulatory / immunology. T-Lymphocytes, Regulatory / metabolism. T-Lymphocytes, Regulatory / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2001 Jun 15;92(6):856-60 [11351307.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 25;97(9):4760-5 [10781081.001]
  • [Cites] Immunol Rev. 2002 Oct;188:22-32 [12445278.001]
  • [Cites] Cancer Immun. 2002 Sep 19;2:12 [12747757.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8862-7 [12853579.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10(3):890-6 [14871964.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10697-702 [15252201.001]
  • [Cites] J Exp Med. 1994 Nov 1;180(5):1599-607 [7964448.001]
  • [Cites] Science. 1996 Oct 4;274(5284):94-6 [8810254.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1914-8 [9050879.001]
  • [Cites] J Exp Med. 1998 Apr 20;187(8):1349-54 [9547346.001]
  • [Cites] J Immunol. 1998 Oct 1;161(7):3598-606 [9759882.001]
  • [Cites] Cancer Res. 1999 Jul 1;59(13):3128-33 [10397255.001]
  • [Cites] Int J Cancer. 1999 Oct 22;84(5):506-10 [10502728.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):263-74 [15776005.001]
  • [Cites] Blood. 2005 Aug 1;106(3):1008-11 [15840697.001]
  • [Cites] Nat Rev Cancer. 2005 Aug;5(8):615-25 [16034368.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43 [16344461.001]
  • [Cites] Adv Cancer Res. 2006;95:1-30 [16860654.001]
  • [Cites] Blood. 2006 Aug 1;108(3):804-11 [16861339.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14453-8 [16984998.001]
  • [Cites] Cancer Sci. 2006 Dec;97(12):1374-80 [16995877.001]
  • [Cites] Cancer Immunol Immunother. 2007 Jan;56(1):88-94 [16622680.001]
  • [Cites] Int J Cancer. 2007 Feb 1;120(3):594-604 [17096336.001]
  • [Cites] Int J Cancer. 2007 May 15;120(10):2178-84 [17278093.001]
  • [Cites] Cancer Immun. 2007;7:9 [17441676.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 22;104(21):8947-52 [17517626.001]
  • [Cites] Cancer Sci. 2007 Jul;98(7):1092-8 [17488334.001]
  • [Cites] Cancer Immunol Immunother. 2008 Aug;57(8):1185-95 [18253733.001]
  • [Cites] Cancer Immunol Immunother. 2008 Oct;57(10):1429-37 [18311489.001]
  • [Cites] Clin Cancer Res. 2009 Mar 15;15(6):2166-73 [19276262.001]
  • [Cites] Lung Cancer. 2009 Jul;65(1):119-22 [19193472.001]
  • [Cites] Cancer Res. 2002 Jan 1;62(1):213-8 [11782380.001]
  • (PMID = 19791734.001).
  • [ISSN] 1424-9634
  • [Journal-full-title] Cancer immunity
  • [ISO-abbreviation] Cancer Immun.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / CTAG1B protein, human; 0 / Epitopes; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Immunoglobulin G; 0 / Interleukin-2 Receptor alpha Subunit; 0 / Membrane Proteins
  • [Other-IDs] NLM/ PMC2935771
  •  go-up   go-down


41. Friedel G, Kuipers T, Dippon J, Al-Kammash F, Walles T, Kyriss T, Veit S, Greulich M, Steger V: Full-thickness resection with myocutaneous flap reconstruction for locally recurrent breast cancer. Ann Thorac Surg; 2008 Jun;85(6):1894-900
MedlinePlus Health Information. consumer health - Breast Reconstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Full-thickness resection with myocutaneous flap reconstruction for locally recurrent breast cancer.
  • BACKGROUND: Despite available recommendations, therapeutic procedures of locally recurrent breast cancer are very different.
  • METHODS: Between 1985 and 2006, 63 women (mean age, 58 years) with local recurrence of breast cancer invading the chest wall underwent chest wall resection with myocutaneous flap coverage and are included in this study.
  • Preoperative known extrapulmonary metastases, pleural dissemination, and Eastern Cooperative Oncology Group (ECOG) status 3 or 4 were exclusion criteria.
  • RESULTS: The median interval between operation for the primary tumor and of the local recurrence was 89 months, with median follow-up at 28 months.
  • Prognostic factors were patient age at the time of the primary operation and tumor invasion of bony structures.
  • CONCLUSIONS: Full-thickness chest wall resection of locally recurrent breast cancer performed by a team of thoracic and plastic surgeons provides the best survival rates, with low mortality and morbidity.
  • [MeSH-major] Breast Neoplasms / surgery. Mammaplasty / methods. Neoplasm Recurrence, Local / surgery. Surgical Flaps

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2008 Jun;85(6):1900 [18498791.001]
  • (PMID = 18498790.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


42. Chen JL, Chen KY, Lin CJ, Perng WC, Chen JH: Carcinosarcoma of the pleura and lung metastasized from a poorly differentiated squamous cell carcinoma of the esophagus. Hematol Oncol Stem Cell Ther; 2010;3(1):47-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinosarcoma of the pleura and lung metastasized from a poorly differentiated squamous cell carcinoma of the esophagus.
  • Transformation of a poorly differentiated squamous cell carcinoma (SCC) of the esophagus into a âcarcinosarcomaâ of the pleura and lung has never been reported and its histogenetic origin is still debated.
  • About 9 months later, rapid progression of lung metastases and pleural effusion were found.
  • Palliative therapy was given and the patient eventually died of the disease 9 months after SCC of the thoracic esophagus was diagnosed and one month after carcinosarcoma of the pleura and lung were confirmed.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinosarcoma / diagnosis. Carcinosarcoma / secondary
  • [MeSH-minor] Esophageal Neoplasms / pathology. Fatal Outcome. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Palliative Care. Pleural Neoplasms / secondary

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20231814.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  •  go-up   go-down


43. Takezawa K, Matsuoka Y, Takao T, Nonomura N, Tomita Y, Okuyama A: [Myxofibrosarcoma of the spermatic cord: a case report]. Nihon Hinyokika Gakkai Zasshi; 2008 Mar;99(3):555-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He underwent left high orchiectomy with clinical diagnosis of testicular tumor.
  • The tumor penetrated deeply into the internal inguinal ring.
  • The tumor was resected as proximally as possible with positive surgical margin at the internal ring.
  • Microscopic examination revealed that the tumor was consisted of myxoid stroma with spindle cells, and there was a large variation in histological findings.
  • Accordingly, the tumor was diagnosed as myxofibrosarcoma, high-grade, of the spermatic cord.
  • Postoperative CT scanning revealed multiple retroperitoneal lymph node metastases.
  • He underwent radiation therapy, but soon developed lung metastases and pleural dissemination, and died 2 months after the operation.
  • [MeSH-major] Fibrosarcoma / diagnosis. Genital Neoplasms, Male / diagnosis. Spermatic Cord
  • [MeSH-minor] Aged. Combined Modality Therapy. Fatal Outcome. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18404885.001).
  • [ISSN] 0021-5287
  • [Journal-full-title] Nihon Hinyōkika Gakkai zasshi. The japanese journal of urology
  • [ISO-abbreviation] Nippon Hinyokika Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 9
  •  go-up   go-down


44. Shitara K, Munakata M, Ishiguro A, Kudo T, Okada R, Tomioka R, Mitobe S, Yokoyama S, Sakata Y: [Colonic perforation in a patient treated with combination chemotherapy for recurrent ovarian clear cell adenocarcinoma]. Gan To Kagaku Ryoho; 2006 Oct;33(10):1497-1500
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Emergency laparotomy was not performed because of poor performance status with multiple lung metastases, pleural effusion and pericardial effusion.
  • Oral intake could be restarted for a while, but she died from tumor progression one and a half months after the diagnosis of perforation.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cecal Diseases / etiology. Intestinal Perforation / etiology. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy
  • [MeSH-minor] Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Colonoscopy. Drainage. Drug Administration Schedule. Fatal Outcome. Female. Humans. Lung Neoplasms / secondary. Middle Aged. Pleural Effusion, Malignant / etiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033246.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


45. Hung HC, Ou HY, Huang JS, Chuang MC, Wu TJ: Tumor-associated Hypercalcemia in a patient with Paget's disease. Kaohsiung J Med Sci; 2008 Mar;24(3):152-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-associated Hypercalcemia in a patient with Paget's disease.
  • After analysis of tumor markers and imaging studies, a clinical diagnosis of pancreatic adenocarcinoma with multiple hepatic and lung metastases with pleural effusion was made.

  • MedlinePlus Health Information. consumer health - Paget's Disease of Bone.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18364276.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


46. Dy Echo AV, Soriano-Estrella AS: Gestational trophoblastic tumor in pregnancy: a case report and review of the literature. Int J Gynecol Cancer; 2006 Mar-Apr;16(2):875-81
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gestational trophoblastic tumor in pregnancy: a case report and review of the literature.
  • A case of gestational trophoblastic tumor (GTT) concurrent with an intrauterine pregnancy is reported in a 21-year-old gravida 2 para 0 (0010) who presented with dyspnea, orthopnea, headache, and blurring of vision at 33 weeks age of gestation.
  • Chest radiograph showed pulmonary metastases, with pleural effusion on both lungs.
  • Several hypotheses regarding its origin, its diagnosis, and its management and prognosis are presented.
  • This case report emphasizes the importance of early diagnosis and treatment to improve the prognosis of both the mother and the infant.
  • [MeSH-minor] Adult. Chlorambucil / therapeutic use. Dactinomycin / therapeutic use. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Methotrexate / therapeutic use. Pregnancy. Treatment Outcome

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CHLORAMBUCIL .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681776.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 18D0SL7309 / Chlorambucil; 1CC1JFE158 / Dactinomycin; YL5FZ2Y5U1 / Methotrexate; MDC protocol
  •  go-up   go-down


47. Maeda R, Isowa N, Onuma H, Miura H, Harada T, Touge H, Tokuyasu H, Kawasaki Y: Lung adenocarcinomas with micropapillary components. Gen Thorac Cardiovasc Surg; 2009 Oct;57(10):534-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results of their clinical presentation, metastasis to lymph nodes, pleural invasion, pathological stage, and clinical outcomes were evaluated.
  • RESULTS: In all, 12 patients underwent a lobectomy or bilobectomy with a regional lymph node dissection; 8 showed metastases to the regional lymph nodes at the time of the operation.
  • Altogether, 14 of 15 cases showed lymphovascular invasion; 10 cases were up-staged after the operation because of lymph node metastases or pleural invasion.
  • CONCLUSION: These results suggest that the micropapillary components are a manifestation of aggressive behavior, as shown by the frequent lymph node metastases and pleural invasion.
  • Surgeons should search more carefully for metastases and conduct a closer follow-up on these patients when this feature is present with lung adenocarcinoma.
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Pleura / pathology. Pneumonectomy. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19830516.001).
  • [ISSN] 1863-6713
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


48. Soria G, Yaal-Hahoshen N, Azenshtein E, Shina S, Leider-Trejo L, Ryvo L, Cohen-Hillel E, Shtabsky A, Ehrlich M, Meshel T, Keydar I, Ben-Baruch A: Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions. Cytokine; 2008 Oct;44(1):191-200
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant expression of the chemokines RANTES and MCP-1 in human breast cancer: a basis for tumor-promoting interactions.
  • In the present study, we asked if the two chemokines are jointly expressed in clinical samples of breast cancer patients, and do they interact in breast tumor cells.
  • We found that RANTES and MCP-1 were expressed by breast tumor cells in primary tumors of Ductal Carcinoma In Situ and of Invasive Ductal Carcinoma, but minimally in normal breast epithelial duct cells.
  • The chemokines were also detected in metastases and pleural effusions.
  • Novel findings showed that co-expression of RANTES and MCP-1 in the same tumor was associated with more advanced stages of disease, suggesting that breast tumors "benefit" from interactions between the two chemokines.
  • Our findings show a chemokine-triggered release of stored pro-malignancy chemokine from breast tumor cells.
  • These observations support a major tumor-promoting role for co-expression of the chemokines in breast malignancy, and agree with the significant association of joint RANTES and MCP-1 expression with advanced stages of breast cancer.
  • [MeSH-minor] Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / pathology. Carcinoma, Intraductal, Noninfiltrating / metabolism. Carcinoma, Intraductal, Noninfiltrating / pathology. Cell Line, Tumor. Female. Gene Expression Regulation, Neoplastic. Humans. Neoplasm Metastasis / physiopathology. Pleural Effusion / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18790652.001).
  • [ISSN] 1096-0023
  • [Journal-full-title] Cytokine
  • [ISO-abbreviation] Cytokine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCL2 protein, human; 0 / CCL5 protein, human; 0 / Chemokine CCL2; 0 / Chemokine CCL5
  •  go-up   go-down


49. Bulbul Y, Oztuna F, Topba M, Ozlu T: Survival analyses of patients with thoracic complications secondary to bronchial carcinoma at the time of diagnosis. Respiration; 2005 Jul-Aug;72(4):388-94
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival analyses of patients with thoracic complications secondary to bronchial carcinoma at the time of diagnosis.
  • BACKGROUND: The impact on survival of thoracic complications secondary to bronchial carcinoma has not been clearly analyzed.
  • OBJECTIVES: The purpose of this study was to assess the significance of these complications for the survival of lung cancer patients.
  • Any intrathoracic change or abnormality secondary to bronchial carcinoma such as atelectasis or pleural effusion was defined a thoracic complication.
  • The complications were atelectasis, pulmonary metastases, pleural effusion, laryngeal nerve involvement, vena cava superior syndrome and others.
  • CONCLUSION: Atelectasis, which was determined to be the most frequent thoracic complication, was identified as a favorable prognostic factor in patients with advanced stage lung cancer.

  • MedlinePlus Health Information. consumer health - Collapsed Lung.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 S. Karger AG, Basel.
  • (PMID = 16088282.001).
  • [ISSN] 0025-7931
  • [Journal-full-title] Respiration; international review of thoracic diseases
  • [ISO-abbreviation] Respiration
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


50. Medford AR, Entwisle JJ: Indications for thoracic ultrasound in chest medicine: an observational study. Postgrad Med J; 2010 Jan;86(1011):8-11

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Thoracic ultrasound (TUS) is increasingly used in chest medicine in secondary care.
  • RESULTS: The most common clinical indication was to assess a pleural effusion in 60/80 cases (75%), but other indications included assessment of diaphragmatic function, pleural thickening and chest wall masses.
  • TUS guided pleural cytology diagnosed pleural fluid metastases in 9/22 cases aspirated (41%).
  • CONCLUSION: There are many clinical indications for TUS but the most common is pleural effusion assessment.
  • TUS can diagnose inoperable pleural metastases, allow safe day case pleural intervention, exclude significant pleural pathology not visible on CXR, and triage further investigation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20065335.001).
  • [ISSN] 1469-0756
  • [Journal-full-title] Postgraduate medical journal
  • [ISO-abbreviation] Postgrad Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


51. Nishiyama A, Yoshioka H, Ishida T: Pleural metastases of malignant melanoma. J Thorac Oncol; 2010 Jun;5(6):908
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleural metastases of malignant melanoma.
  • [MeSH-major] Melanoma / secondary. Pleural Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20502270.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Suchak AA, Millo N, MacEwan R, McEwan AJ: Neuroendocrine differentiated breast carcinoma with pleural metastases using indium-111 octreotide. Clin Nucl Med; 2009 Feb;34(2):74-5
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine differentiated breast carcinoma with pleural metastases using indium-111 octreotide.
  • [MeSH-major] Breast Neoplasms / diagnosis. Breast Neoplasms / pathology. Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Neuroendocrine / pathology. Neoplasm Metastasis / diagnosis. Octreotide / analogs & derivatives

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19352254.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / indium-111-octreotide; RWM8CCW8GP / Octreotide
  •  go-up   go-down


53. Kamiyoshihara M, Ibe T, Takise A, Itou H, Takeyoshi I: Pleural metastases from renal cell carcinoma 16 years after resection. J Clin Oncol; 2007 Sep 1;25(25):4009-11
MedlinePlus Health Information. consumer health - Kidney Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleural metastases from renal cell carcinoma 16 years after resection.
  • [MeSH-major] Carcinoma, Renal Cell / secondary. Carcinoma, Renal Cell / surgery. Kidney Neoplasms / surgery. Pleural Neoplasms / diagnosis. Pleural Neoplasms / secondary

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17761985.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Muljono A, Ng T, McMaster J, Dexter M: Choroid plexus metastases from pleural sarcomatoid mesothelioma. Pathology; 2008 Aug;40(5):530-2
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroid plexus metastases from pleural sarcomatoid mesothelioma.
  • [MeSH-major] Choroid Plexus Neoplasms / secondary. Mesothelioma / secondary. Pleural Neoplasms / pathology
  • [MeSH-minor] Aged. Brain Neoplasms / pathology. Diagnosis, Differential. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18604744.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


55. Salloum H, Locher C, Kassem M, Grivaux M, Glikmanas M, Locher C: [Malignant pleural effusions of pancreatic carcinoma]. Gastroenterol Clin Biol; 2006 Jan;30(1):156-7
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant pleural effusions of pancreatic carcinoma].
  • [Transliterated title] Métastases pleurales d'un adénocarcinome pancréatique.
  • [MeSH-major] Adenocarcinoma / pathology. Pancreatic Neoplasms / pathology. Pleural Effusion, Malignant / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16514403.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; Letter
  • [Publication-country] France
  •  go-up   go-down






Advertisement